Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab biomarker monitoring study for progression prediction in multiple sclerosis
NL-OMON61538Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ofatumumab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: Time to physical and/or cognitive progression over 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON61538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61538.